Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?

Nephrol Dial Transplant. 2007 Jan;22(1):32-6. doi: 10.1093/ndt/gfl573. Epub 2006 Oct 20.

Author

Christopher F Wong¹

Affiliation

¹ Department of Nephrology, University Hospital Aintree, Lower Lane, Liverpool L9 7AL, UK. chriswong@doctors.org.uk

PMID: 17056639
DOI: 10.1093/ndt/gfl573

No abstract available

Publication types

Review

MeSH terms

Antibodies, Antineutrophil Cytoplasmic / metabolism*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Antibody Formation
B-Lymphocytes / metabolism
Clinical Trials as Topic
Cytoplasm / metabolism*
Granulomatosis with Polyangiitis / drug therapy
Humans
Immunologic Factors / adverse effects
Immunologic Factors / therapeutic use*
Models, Biological
Neutrophils / immunology*
Rituximab
Vasculitis / drug therapy*

Substances

Antibodies, Antineutrophil Cytoplasmic
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors
Rituximab